Karolinska Development Sells Its Stake in Henlez ApS
Karolinska Development AB has just announced the complete sale of its shares in Henlez ApS, a notable milestone in its investment approach. Now, with this transaction finalized, Karolinska Development's portfolio comprises eleven distinct holdings, reflecting a sharpened strategic focus.
Details of the Divestment
This divestment follows Karolinska Development's investment in Henlez, made in collaboration with Eir Ventures, a respected Nordic venture capital firm, back in 2022. Henlez ApS specializes in developing treatments for hidradenitis suppurativa, a chronic skin condition. Before the sale, Karolinska Development held a 15% stake in Henlez, highlighting its commitment to this innovative healthcare venture.
Strategic Intent and Future Vision
The decision to divest aligns with Karolinska Development's strategy to fine-tune its investment portfolio. By letting go of non-core assets, the company aims to focus its resources on sectors with greater growth prospects. This approach is not just about improving financial outcomes; it also positions Karolinska Development to better support the ongoing development of its remaining portfolio companies.
Investment Philosophy of Karolinska Development
Karolinska Development stands out for its thorough investment philosophy, which centers on discovering pioneering medical innovations in the Nordic region. The firm works closely with leading scientists and research institutions to bring innovative healthcare solutions to life, targeting critical health challenges.
Commitment to Innovation in Healthcare
With connections to world-class medical innovations at the esteemed Karolinska Institutet and other leading research bodies, Karolinska Development builds companies rooted in cutting-edge scientific ideas. The ultimate aim is to transform these ideas into practical products that can significantly improve patients' lives while providing returns to its stakeholders.
Leadership Expertise and Guidance
Karolinska Development's leadership team features experienced investment professionals who have a proven track record in building successful healthcare businesses. Their entrepreneurial spirit and expertise are vital in navigating the intricate landscape of the life sciences industry, ensuring that portfolio companies receive the necessary support to flourish.
Diverse Portfolio of Innovations
The firm has developed a varied portfolio that comprises eleven companies, each aimed at addressing life-threatening and debilitating diseases. These companies showcase innovative treatment approaches and are positioned to make a real difference in healthcare.
A Commitment to Future Growth
The strategic direction of Karolinska Development underscores growth and innovation within all its holdings. By leveraging a strong network of international investors and top-tier management teams, the firm enhances the likelihood of successful product development and introduction to the market.
Contact Information
For more information regarding this divestment and the operations of Karolinska Development, interested individuals can contact:
Viktor Drvota, CEO,
Phone: +46 73 982 52 02,
Email: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO,
Phone: +46 70 207 48 26,
Email: johan.dighed@karolinskadevelopment.com
Frequently Asked Questions
Why did Karolinska Development decide to divest from Henlez?
The divestment is part of Karolinska Development's strategy to streamline its investment portfolio and focus on areas with higher growth potential.
What was Karolinska Development's ownership percentage in Henlez before the sale?
Before selling, Karolinska Development held a 15% stake in Henlez ApS.
Who was the partner of Karolinska Development in investing in Henlez?
Karolinska Development teamed up with Eir Ventures, a Nordic venture capital firm, for its investment in Henlez.
What is the main focus of Karolinska Development as an investment company?
The firm primarily concentrates on identifying and nurturing breakthrough medical innovations from entrepreneurial teams in the Nordic region.
How does Karolinska Development assist its portfolio companies?
They offer strategic guidance, financial backing, and access to a robust network of investors and industry expertise to maximize the chances of success for the companies in their portfolio.